findmyKOL

Sakima Smith, MD

Basic profile

The Ohio State University Wexner Medical Center

ORCIDNPI
RegionColumbus, OH · MidwestSpecialtyCardiovascular DiseaseFocusCardiology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH funding2017–2025

Sakima Smith is a Cardiology physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 157 publications with 1,748 citations (h-index 26).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
157publications

Distinct works indexed by OpenAlex, matched via ORCID.

1,748citations

Total citations across indexed works.

26h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
4NIH grants · 2017–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

473 W 12th Ave
Suite 200
Columbus, OH 432101252

Telephone

614-293-8962

Registry record last updated 2 Jul 2014.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    80.3%
    Beta blocker21.4%
    Metoprolol Succinate74%Carvedilol27%
    Part D29 patients
    Angiotensin receptor-neprilysin inhibitor (ARNI)15%
    Entresto100%
    Part D16 patients

    + 7 more classes in this area

  • Metabolism & gastrointestinal

    11.8%
    SGLT2 inhibitor4.7%
    Farxiga100%
    Part D<11 patients
    Potassium supplement4.6%
    Potassium Chloride100%
    Part D<11 patients

    + 1 more class in this area

  • Blood & clotting

    8%
    Factor Xa inhibitor4.9%
    Eliquis100%
    Part D<11 patients
    Vitamin K antagonist3%
    Warfarin Sodium100%
    Part D<11 patients
Where care is delivered (Part B)53.6% facility · 46.4% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

4 NIH research awards on record, funded 20172025 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”